Genetika+
DNA based sequencing and analysis for drug response predictions for depression. Market is booth physicians and pharma companies
Company Name | Updating Date | Neurotech Category | Market Category | Target Market | Technologies | Company Founded Year | Company Number of Employees |
|---|---|---|---|---|---|---|---|
Genetika+ | 02/07/2022 | NeuroPharmacology | NeuroBioTechnology | Biotechnology & Biopharmaceutical | Medical use (pharma, nerve damage rehabilitation, neurodiagnostics. inc. early diagnosis) | Diagnostics | 01/01/2018 | "11-50" |
Genetika+ is developing a personalized medical testing tool to better
treat depression by helping physicians find the best drug therapy for
their patients. The Genetika+ test helps predict the best drug treatment
for each patient, enabling faster treatment, fewer side effects, and
lower dosing.
The company's platform assists pharmaceutical companies in their drug
development pipeline by providing robust and highly specific drug
response predictions from a broad group of patients. It includes a fully
profiled and replenishable model for major depression, allowing a rapid
high-throughput identification of novel drugs and their molecular
effects on cells. It also allows the identification of patient subsets
for clinical trials, obviating the need for larger clinical trials and
increasing the potential for successful outcomes.